
Rheumatologist and Internist @ABCcentromedico | Professor @TECccm Former Research Fellow, Division of rheumatology @MayoClinic, Rochester, MN
Rochester, MN
Joined September 2013
- Tweets846
- Following317
- Followers255
- Likes3.1K
Alain Sanchez, MD retweeted
Not all bone marrow oedema is spondyloarthritis!
Osteitis condensans ilii can mimic sacroiliitis on MRI. Recognising its characteristic imaging features is essential to avoid misdiagnosis.
#SpA #Spondyloarthritis #OsteitisCondensansIlii
Alain Sanchez, MD retweeted
1/ SLE is not confined to young women. Across 6 CDC-supported, population-based lupus registries (including LUMEN💡)—we examined how SLE incidence varies across demographic groups in diverse U.S. populations.
acrjournals.onlinelibrary.wi…
Alain Sanchez, MD retweeted
In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)?
buff.ly/tvebmPZ
Alain Sanchez, MD retweeted
🫁 ERS/EULAR 2026 CTD-ILD Guidelines — Key Takeaways
🔹 Covers SSc, RA, IIM, Sjögren, SLE & MCTD–ILD
🔹 Built on 25 PICO + 28 narrative questions using GRADE methodology
📌 Screening
👉 HRCT = gold standard
🚫 Do NOT replace HRCT with PFTs or lung ultrasound (high miss rates)
✅ Screen ALL SSc & MCTD
✅ Screen RA / SjD / IIM if risk factors present
📌 Baseline risk assessment
Assess globally using:
• HRCT extent/pattern
• FVC + DLCO
• Autoantibodies
• CRP/ESR
• Clinical severity
📌 Monitoring
🔁 PFTs every 3–6 months initially, then 6–12 monthly
🔁 HRCT:
• SSc/RA: every 1–2 yrs
• IIM (high-risk): as early as 3–6 months
📌 Treatment recommendations
🟢 SSc-ILD
• Tocilizumab (strong)
• MMF / Rituximab / Cyclophosphamide (conditional)
• Nintedanib for progressive fibrosis
• MMF + Nintedanib combination allowed
🟢 IIM-ILD
• Immunosuppression strongly recommended
🟢 RA / SjD / SLE / MCTD-ILD
• Immunosuppressants suggested
• RA-ILD (UIP): Pirfenidone may help
🟢 Progressive fibrosing CTD-ILD
• Add Nintedanib
🚫 Lung biopsy NOT routine
✅ BAL only if infection / alternate dx suspected
✅ PROMs + 6MWT for severity/prognosis
⸻
🔥 TAKE-HOME MESSAGE
Early HRCT screening + structured monitoring + timely immunosuppression/antifibrotics = cornerstone of CTD-ILD care. Missing ILD = missed survival opportunity.
⸻
📄 Eur Respir J 2026
DOI: 10.1183/13993003.02533-2024
#CTDILD #InterstitialLungDisease #Rheumatology #Pulmonology #SystemicSclerosis #RA #Myositis #Sjogrens #SLE #ERS #EULAR #ILD #MedTwitter #RheumTwitter #PulmTwitter
Alain Sanchez, MD retweeted
Volver a México y compartir con colegas siempre es una alegría: colegas increíbles, preguntas buenísimas y mucha conversación. Gracias al Colegio Mexicano de Reumatología por la invitación. 🇲🇽
Alain Sanchez, MD retweeted
Call for new applicants for Rheum With a (re)View—a mentoring program focused on cultivating manuscript reviewers for the ACR’s 3 scientific journals. ACR/ARP members with research experience are encouraged to apply by March 31
▶️ Details → rheumatology.org/acr-journal…
Alain Sanchez, MD retweeted
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
➠ Read the Full Guideline: acr.tw/47mkegj
#RheumX #RheumTwitter #Rheum @RheumNow
Alain Sanchez, MD retweeted
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W

ALT LEGEND: Overview of the recommended management for systemic lupus erythematosus (SLE). This schematic illustrates the approach to SLE treatment, with organ-specific therapies presented in separate boxes and stratified by disease severity. The order of the medications in each box does not indicate preference unless noted otherwise. Lupus nephritis treatment is addressed in the 2025 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis. (see paper for footnotes)
Alain Sanchez, MD retweeted
Over 20 years have passed since the ACR last issued a broad treatment guideline for #SLE. In our NEWEST episode, Lisa R. Sammaritano, MD, summarizes the major updates in the soon-to-be-released 2025 guideline.🎙️LISTEN → acr.tw/4mTmpNi
Alain Sanchez, MD retweeted
#ESOC2025
🏃🏻♀️ESCAPE MEVO sub analysis
👉🏻 prognosis by image 🧠
👉🏻EVT <12 hs not > good functional outcome
👉🏻 Good collateral status > benefit
👉🏻 ⏱️<180 min > benefit
Alain Sanchez, MD retweeted
1/ 🧵The 2024 ACR Guidelines for Lupus Nephritis (LN) are here! Big shifts in screening, combo therapy, and steroid minimization. Let's break it down. Full text: acrjournals.onlinelibrary.wi…
Alain Sanchez, MD retweeted
Now published simultaneously in AC&R + A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis
See ACR guideline page for resources - rheumatology.org/lupus-guide…
DOI link - doi.org/10.1002/acr.25528
Download the article - acr.tw/44sRwJM
Alain Sanchez, MD retweeted
Rheumatologist when someone automatically calls an ANA (+) “undifferentiated connective tissue disease”
Alain Sanchez, MD retweeted
NEW! Curious about how genetics influence autoimmune disease risk? Tune in & hear from @HocaogluMd, who dives into the study of antinuclear antibody production using data from the All of Us Research Program → acr.tw/42d7QN2 @ACR_Journals
Alain Sanchez, MD retweeted
🔟 Final Takeaways
✅ Obi improved renal outcomes in active LN
✅ Steroid-sparing effect (more Obi pts tapered to ≤7.5 mg/day)
✅ Proteinuria reduction = better long-term kidney survival
✅ Infections (esp. COVID-19) are a key safety concern
Alain Sanchez, MD retweeted
🚨 Breaking down the REGENCY trial 🚨
A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️
Alain Sanchez, MD retweeted
🚨 New Review Alert! 🚨
Dive into the evolving landscape of glucocorticoid therapy for lupus nephritis:
🔍 Historical shifts from high-dose to safer, low-dose strategies
🧬 Mechanisms, efficacy, & risks explored
⚖️ Balancing treatment efficacy with long-term safety
Now online in @NDTsocial
Optimal Glucocorticoid Therapy in Lupus Nephritis
🧐The review examines different dosing strategies, including IV pulse and oral regimens, and presents evidence of their efficacy and safety.
▶️academic.oup.com/ndt/article…
Alain Sanchez, MD retweeted
Usually everything from @drlalonares is quite interesting. This was not the exemption
#ACR24
👉🏼Presenting our recent work: Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease
@FuruzawaJanette
#ACR24 #ACR2024 #IgG4RD @IgG4ward @ReumaJoven @PanlarJ































